ACT Genomics
Taipei, Taiwan· Est.
ACT Genomics delivers NGS‑based genomic profiling to personalize cancer treatment across Asia.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
ACT Genomics delivers NGS‑based genomic profiling to personalize cancer treatment across Asia.
Oncology
Technology Platform
NGS‑based tumor DNA sequencing coupled with a proprietary bioinformatics pipeline that delivers actionable biomarker reports for solid tumors.
Opportunities
Expansion into liquid‑biopsy assays and AI‑driven analytics, plus deeper collaborations with biopharma for companion‑diagnostic development across Asia.
Risk Factors
Regulatory changes, intense competition from global NGS providers, and reliance on a limited geographic market could constrain growth.
Competitive Landscape
Competes with Guardant Health, Foundation Medicine, and local NGS labs; differentiates through FDA‑cleared IVD for Asian populations and strong regional clinical network.